SCHEMBL6008063

SCHEMBL6008063

S=[C]NCc1cccc2nc3ccccc3nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
RAB9A P51151 3/20 0.42
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NQO2 P16083 6/20 0.39
ACHE P22303 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
TDP1 Q9NUW8 1/20 0.32
TERT O14746 1/20 0.32
NPC1 O15118 2/20 0.32
KDM4E B2RXH2 1/20 0.32
THRB P10828 1/20 0.32
MAPK1 P28482 1/20 0.32
BLM P54132 1/20 0.32
ATM Q13315 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6007426 0.83 MAPT (0.42) MAPTRAB9AKMT2AALDH1A1GAA
SCHEMBL6008068 0.77 MAPT (0.42) MAPTRAB9AKMT2AALDH1A1GAA
SCHEMBL6006490 0.76 KMT2A (0.46) MAPTRAB9AKMT2AALDH1A1GAA
SCHEMBL6007433 0.73 ADH1B (0.43) MAPTRAB9AKMT2AALDH1A1GAA
SCHEMBL6473213 0.71 MAPT (0.50) MAPTRAB9AKMT2AALDH1A1GAA
SCHEMBL6007386 0.71 MAPT (0.50) MAPTRAB9AKMT2AALDH1A1GAA
SCHEMBL3414003 0.71 NQO2 (0.50) MAPTRAB9AKMT2AALDH1A1GAA
SCHEMBL291536 0.71 MAPT (0.50) MAPTRAB9AKMT2AALDH1A1GAA
SCHEMBL9934669 0.71 MAPT (0.50) MAPTRAB9AKMT2AALDH1A1GAA
SCHEMBL9934672 0.71 ALDH1A1 (0.55) MAPTRAB9AKMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 MAPT 4279/4885RAB9A 965/4885KMT2A 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.